Evaxion Biotech A/S (EVAX): Price and Financial Metrics
EVAX Price/Volume Stats
| Current price | $4.18 | 52-week high | $18.50 |
| Prev. close | $4.12 | 52-week low | $2.82 |
| Day low | $4.02 | Volume | 25,100 |
| Day high | $4.33 | Avg. volume | 531,819 |
| 50-day MA | $3.59 | Dividend yield | N/A |
| 200-day MA | $7.11 | Market Cap | 21.80M |
EVAX Stock Price Chart Interactive Chart >
Evaxion Biotech A/S (EVAX) Company Bio
Evaxion Biotech A/S operates as a biotechnology company. The Company develops AI-immunology platform for decoding human immune system to discover and develop immunotherapies for cancer and infectious diseases treatment. Evaxion Biotech serves patients in Denmark.
Latest EVAX News From Around the Web
Below are the latest news stories about EVAXION BIOTECH A that investors may wish to consider to help them evaluate EVAX as an investment opportunity.
Evaxion Biotech Announces Closing of Private PlacementMSD Global Health Innovation Fund (MSD GHI), a corporate venture capital arm of Merck & Co., Inc., Rahway, NJ, USA, is contributing with some 25% of the total offering amount Company’s management and board of directors with significant participation in the total offering COPENHAGEN, Denmark, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced |
EVAX Stock Earnings: Evaxion Biotech Misses EPS for Q3 2023EVAX stock results show that Evaxion Biotech missed analyst estimates for earnings per share the third quarter of 2023. |
Evaxion Announces Business Update and Third Quarter 2023 Financial ResultsThe Evaxion Three-Pronged Strategy Evaxion Announces Business Update and Third Quarter 2023 Financial Results Christian Kanstrup joined Evaxion as Chief Executive Officer in SeptemberEvaxion has launched its refined strategy with an increased focus on value realization via partnerships based upon the AI-Immunology™ platformSolid progress has already been seen on the refined strategy with two partnerships announced in Q3 and proof-of-principle for Evaxion’s proprietary responder model based upon |
Evaxion Biotech Announces Private Placement FinancingMSD Global Health Innovation Fund (MSD GHI), a corporate venture capital arm of Merck & Co., Inc., Rahway, NJ, USA, is contributing with some 25% of the total offering amount Company’s management and board of directors with significant participation in the total offering COPENHAGEN, Denmark, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, is pleased to a |
Evaxion to Unveil Potentially Groundbreaking AI-Immunology™ Precision Cancer Vaccine ConceptProof of Concept – Evaxion’s AI-Immunology™ platform demonstrates success in designing precision cancer vaccines in hematological cancers by targeting a novel class of antigensBroad Applicability – The vaccine concept holds tremendous potential, offering broad applicability and promising benefits for patients with hematological malignancies COPENHAGEN, Denmark, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company spec |
EVAX Price Returns
| 1-mo | N/A |
| 3-mo | -36.18% |
| 6-mo | -62.68% |
| 1-year | -66.83% |
| 3-year | -94.31% |
| 5-year | N/A |
| YTD | -39.04% |
| 2023 | -61.37% |
| 2022 | -59.84% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...